Hey Blue,
Those were there before as I remember the DOD there as well and liked the look of seeing their logo there.
I really can't see $8 million taking them to the finish line, even with adaptive pathways. Sure the trial sizes are small, but I think it involves more follow up visits over a longer period of time. Those costs will be huge IMO.
I was looking into BLUE. Bluebird bio not you Blue. They have $1.2 billion in cash and state they have enough to last to 2020. They have 350 employees and have 10 active or soon to be active trials according to clinical trials. I'm sure many of the 37 total found are still gathering results and costing money.
We have $22 mil, (less once quarter comes out) $24 or so in grants plus our ATM funds. We have 170 employees and 2 active trials. Look at that eh, we have approximately half the number of employees as a $5.7 billion market cap biotech. Ahhhhh. But we have all those manufacturing employees to pay I guess.
Just goes to show the extraordinary amount of money it takes to get these things done. Thats why big pharma preys on small biotechs. And going it alone brings about huge risks, most of which are just denied by some on this board.
Where are the HCT interim results or NYBC preclinical results. 3+ months late according to their January presentation. I know the September ones show 2h, so don't throw the normal insults towards me please. But even if you want to, feel free as I can take it.
Been a nice run of late at least. Hopefully we can hold it until something of significance comes out. The ATM gives me mixed emotions. Sure it gives the much needed cash, but where would the price be if they weren't selling into this recent run. Who knows, maybe they didn't. Probably did, but NOBODY knows for sure until next quarter comes out. Unless they had insider information or course.
GLTA longs. I am one too even though I never said what type of options I own. Just thought people would have realized that or I would not have been complaining if I had puts when we were stuck down there.
